US Bancorp’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-15
| Closed | -$292 | – | 4140 |
|
|
2023
Q2 | $292 | Sell |
15
-610
| -98% | -$14.5K | ﹤0.01% | 3907 |
|
|
2023
Q1 | $17.7K | Sell |
625
-171
| -21% | -$5.08K | ﹤0.01% | 3049 |
|
|
2022
Q4 | $23.3K | Buy |
796
+278
| +54% | +$8.84K | ﹤0.01% | 2920 |
|
|
2022
Q3 | $14K | Sell |
518
-361
| -41% | -$13.2K | ﹤0.01% | 3240 |
|
|
2022
Q2 | $39K | Buy |
879
+302
| +52% | +$13.9K | ﹤0.01% | 2723 |
|
|
2022
Q1 | $29K | Sell |
577
-7,160
| -93% | -$344K | ﹤0.01% | 2886 |
|
|
2021
Q4 | $394K | Sell |
7,737
-81
| -1% | -$4.2K | ﹤0.01% | 1650 |
|
|
2021
Q3 | $437K | Sell |
7,818
-500
| -6% | -$24.6K | ﹤0.01% | 1589 |
|
|
2021
Q2 | $356K | Sell |
8,318
-313
| -4% | -$12.9K | ﹤0.01% | 1720 |
|
|
2021
Q1 | $361K | Buy |
8,631
+44
| +0.5% | +$2.04K | ﹤0.01% | 1662 |
|
|
2020
Q4 | $399K | Sell |
8,587
-159
| -2% | -$7.44K | ﹤0.01% | 1561 |
|
|
2020
Q3 | $371K | Sell |
8,746
-731
| -8% | -$32K | ﹤0.01% | 1491 |
|
|
2020
Q2 | $454K | Sell |
9,477
-842
| -8% | -$42K | ﹤0.01% | 1347 |
|
|
2020
Q1 | $475K | Buy |
10,319
+189
| +2% | +$9.48K | ﹤0.01% | 1229 |
|
|
2019
Q4 | $608K | Buy |
10,130
+1,000
| +11% | +$59.6K | ﹤0.01% | 1270 |
|
|
2019
Q3 | $517K | Buy |
9,130
+861
| +10% | +$48.4K | ﹤0.01% | 1353 |
|
|
2019
Q2 | $460K | Buy |
8,269
+427
| +5% | +$22.3K | ﹤0.01% | 1444 |
|
|
2019
Q1 | $396K | Buy |
7,842
+543
| +7% | +$24.2K | ﹤0.01% | 1495 |
|
|
2018
Q4 | $295K | Buy |
7,299
+4,087
| +127% | +$211K | ﹤0.01% | 1581 |
|
|
2018
Q3 | $223K | Buy |
3,212
+445
| +16% | +$33.7K | ﹤0.01% | 1812 |
|
|
2018
Q2 | $209K | Buy |
2,767
+1,819
| +192% | +$114K | ﹤0.01% | 1849 |
|
|
2018
Q1 | $50K | Hold |
948
| – | – | ﹤0.01% | 2624 |
|
|
2017
Q4 | $51K | Hold |
948
| – | – | ﹤0.01% | 2592 |
|
|
2017
Q3 | $57K | Sell |
948
-61
| -6% | -$3.69K | ﹤0.01% | 2515 |
|
|
2017
Q2 | $80K | Hold |
1,009
| – | – | ﹤0.01% | 2309 |
|
|
2017
Q1 | $84K | Buy |
1,009
+61
| +6% | +$4.54K | ﹤0.01% | 2236 |
|
|
2016
Q4 | $75K | Hold |
948
| – | – | ﹤0.01% | 2251 |
|
|
2016
Q3 | $66K | Buy |
948
+85
| +10% | +$4.71K | ﹤0.01% | 2295 |
|
|
2016
Q2 | $33K | Hold |
863
| – | – | ﹤0.01% | 2607 |
|
|
2016
Q1 | $35K | Buy |
+863
| New | +$54.8K | ﹤0.01% | 2545 |
|
Other funds holding EGRX
BIP
US Bancorp's EGRX Position: Q3 2023 in Review
US Bancorp sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 15 shares — an estimated $292 sold.
US Bancorp first reported a position in EGRX in Q1 2016 and held it in 30 quarters. The position peaked at $608K in Q4 2019. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.
- US Bancorp reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- US Bancorp sold 15 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $292.
- US Bancorp first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 30 quarters.
- US Bancorp's Eagle Pharmaceuticals, Inc. position peaked at $608K in Q4 2019.
- 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.
Based on US Bancorp's 13F filing for Q3 2023, filed 3 Nov 2023.